Revenue, 2025

USD 5.84 Billion

Forecast, 2035

USD 13.72 Billion

CAGR, 2026-2035

8.92%

Report Coverage

Global

Dry Age-Related Macular Degeneration Market

The global dry age-related macular degeneration market size is calculated at USD 5.84 billion in 2025, where it continues to grow in 2026 at USD 6.36 billion due to increasing approval of targeted therapies. It is expected to reach USD 13.72 billion by 2035 with a CAGR of 8.92% due to growing geographic atrophy treatment options. North America accounted for 41% of the market in 2025 due to high product approvals.

Key Takeaways Dry Age-Related Macular Degeneration Market

• Dry age-related macular degeneration industry poise to reach USD 6.36 billion by 2026.
• Forecasted to grow to USD 13.72 billion by 2035.
• Expected to maintain a CAGR of 8.92% from 2026 to 2035.
• North America held the major revenue share of 41% in the global dry age-related macular degeneration market in 2025.
• Asia Pacific held a 22% share of the market in 2025 and is expected to grow at the fastest CAGR of 10.63% during the forecast period.
• By disease stage type, the intermediate dry AMD segment held a dominant revenue share of 43% of the market in 2025.
• By disease stage type, the advanced dry AMD (geographic atrophy) segment held 35% of market share in 2025 and is expected to grow at the fastest CAGR of 11.42% during the forecast period.
• By treatment type, the complement inhibitors segment held a dominant revenue share of 31% of the market in 2025.
• By treatment type, the cell-based therapies segment held 9% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By route of administration type, the intravitreal injection segment held a dominant revenue share of 63% of the market in 2025.
• By route of administration type, the oral segment held 16% of market share in 2025 and is expected to grow at the fastest CAGR of 12.14% during the forecast period.
• By end user, the hospitals segment held a dominant position in the market with a share of 42% in 2025.
• By end user, the ophthalmology clinics segment held 30% of the market in 2025 and is expected to grow at the fastest CAGR of 10.34% during the forecast period.
• By distribution channel type, the hospital pharmacies segment held a dominant revenue share of 46% of the market in 2025.
• By distribution channel type, the specialty pharmacies segment held 20% of market share in 2025 and is expected to grow at the fastest CAGR of 11.64% during the forecast period.

Market Overview

Understanding the Dry Age-Related Macular Degeneration Market Landscape

What is Dry Age-Related Macular Degeneration?

Dry age-related macular degeneration refers to the chronic eye disease leading to gradual deterioration of the macula due to aging, which causes slow loss of vision. The common symptoms include blurred vision, need for more bright light, and a dark spot in the center of vision. Based on the information gathered by Payal Rabde, the market is driven by a growing geriatric population and approval of targeted therapies.

Evolution of Dry AMD Treatment

Previously, nutritional supplements were recommended for the treatment of AMD due to limited treatment options, while growing advances in disease diagnostics increased R&D activities. This in turn increased the development of advanced targeted therapies with specific action on genetic factors, risk factors, and pathological hallmarks. Thus, treatment has evolved from nutritional supplementation toward targeted complement inhibition, regenerative medicine, and gene therapy

Disease Burden and Epidemiology Snapshot

The global prevalence of AMD is increasing due to a rise in the aging population, geographic atrophy prevalence, and visual impairments. It is mostly observed after the age of 50 were obesity, cardiovascular disease, and smoking are its major epidemiological risk factors.

Market Trends

Current Industry Trends Transforming Dry AMD Treatment

It highlights pipeline trends, clinical trial growth, and technology adoption timeline, along with other major commercial and scientific trends.

• Increasing Adoption of Complement Inhibitors: They help in targeting underlying disease pathology, which has increased their demand.
• Expansion of Geographic Atrophy Treatment Market: Growing targeted therapies, focus on preservation of vision, and increasing diagnostic rates are increasing their use.
• Rising Clinical Development Activity: Increasing investments and collaborations are driving the development of novel therapies and increasing clinical trials.
• Growing Interest in Cell and Gene Therapies: These therapies target retinal degeneration, which encourages innovation with the application of advanced dry AMD.
• Artificial Intelligence in Retinal Imaging: It helps in accurate disease detection, precise image analysis, faster clinical decisions, and reduces workload and manual errors.
• Digital Ophthalmology and Remote Monitoring: They help in continuous patient monitoring, enabling remote eye care services, and enhance patient convenience.
• Personalized Treatment Planning: It promotes the development of patient-specific treatment, enhances treatment effectiveness, and improves patient outcomes.
• Biomarker-Based Disease Monitoring: It supports early disease identification and personalized treatment development.
• Increasing Ophthalmology Screening Programs: It helps in early disease diagnosis, reduces risk of further complications, and increases patient awareness.
• Healthcare Spending on Retinal Disorders: They are driven by growing age-related eye disease, rising demand for advanced diagnostics and effective therapeutic options.

Market Dynamics

Market Drivers

• Growing Global Elderly Population: It increases the chances of AMD prevalence, driving the demand for diagnostic and treatment options.
• Rising Prevalence of Geographic Atrophy: This growing incidence increases the demand for advanced therapies and patient monitoring solutions.
• Recent Regulatory Approvals: They promote innovation and increase availability of new treatment options.
• Improved Early Diagnosis: They help in effective management of diseases, provide early interventions, and improve outcomes.
• Growing Healthcare Investments: They accelerate R&D, promote innovations, and enhance infrastructure.

Market Restraints

• High Cost of Novel Therapies: They reduce the adoption rates.
• Limited Treatment Accessibility: Shortage of specialists and high costs reduce treatment adoption.
• Intravitreal Injection Burden: They increase patient discomfort and infection changes which reduces their use.
• Delayed Diagnosis in Developing Nations: Limited awareness and limited diagnostic solutions delay their diagnosis.

Market Opportunities

• Expansion into Emerging Markets: Growing health awareness and healthcare spending are driving the development of new dry AMD treatments and diagnostic options.
• Combination Therapy Development: They improve treatment efficacy and address multiple disease pathways.
• AI-Based Disease Monitoring: They help in early disease diagnosis, improve treatment efficacy, and support the development of personalized solutions.
• Regenerative Medicine: They help in restoring damaged retinal cells and overcoming underlying causes.
• Long-Acting Drug Delivery: They help in minimizing dosing frequency, improving patient convenience, and treatment adherence.
• Personalized Medicine: They enhance therapeutic effectiveness and improve safety profile.

Market Challenges

• Treatment Compliance: Long-term treatment approach, high cost, and limited availability reduce treatment compliance.
• Limited Long-Term Clinical Data: Safety and efficacy uncertainties limit their adoption.
• Reimbursement Complexity: High innovation cost and lengthy coverage approval process increase reimbursement complexities.
• Clinical Trial Recruitment: Limited participants and difficulty in detecting suitable patients slow down clinical activity.

Industry Value Chain Analysis

Complete Industry Ecosystem

It helps cover every stakeholder involved from research through commercialization in the market.

• Basic Research: Highlights research activities focusing on AMD disease mechanism, biomarker discovery, and use of AI imaging solutions.
• Drug Discovery: It covers the development of complement inhibitors, cell therapies, regenerative treatments, and neuroprotective therapeutic options.
• Clinical Development: They are driven by growing advancements in geographic atrophy therapies and imaging biomarkers.
• Manufacturing: They highlight expansion of advanced therapy manufacturing, adoption of automated manufacturing technologies, and new collaborations.
• Distribution: They revolve around growing specialty distribution networks, cold chain logistics, and digital supply chain networks.
• Hospitals & Clinics: They drive the adoption of advanced retinal imaging tools, new treatment options, and promote screening programs.
• Patients: Their volume is increasing due to growing awareness, demand for personalized treatments, and a shift towards vision preservation solutions.

Market Ecosystem Analysis

Stakeholder Mapping: It focuses on the influence of dry age-related macular degeneration products on pharmaceutical companies, biotechnology companies, contract research organizations, CDMOs, regulatory agencies, healthcare providers, insurance companies, patient advocacy groups, and research institutions.

Epidemiology and Patient Pool Analysis

Global Disease Burden

It outlines current diagnosed patients, the undiagnosed population, geographic atrophy prevalence, and disease progression statistics.

• By Age Group: The high risk of dry AMD is observed in individuals above 50 years of age.
• By Gender: Women contribute to the large patient population with slightly higher prevalence rates than men.
• By Disease Stage: A large population contributes to the early stage, with a moderate population in the intermediate stage, and a smaller population in advanced stages.
• By Geography:  The region with a high geriatric population contributes to its growing prevalence rates.

Technology and Innovation Landscape

Emerging Technologies Transforming Dry AMD Care

It encompasses advanced therapies, imaging platforms, monitoring systems, and drug delivery systems.

• Complement Pathway Research: It focuses on retinal inflammation and cell damage for the prevention of disease progression.
• Stem Cell Platforms: They utilize stem cells to develop retinal cells and replace damaged cells.
• Gene Editing: They help to modify disease related gene to correct genetic defects.
• AI Diagnostics: It supports analysis of retinal images, early disease diagnosis, and accelerates R&D activities.
• OCT Imaging Innovations: They provide high-resolution images promoting early disease diagnosis and treatment.
• Sustained Drug Delivery: They help in reducing dosing frequency and improving treatment adherence.
• Digital Monitoring Platforms: They help in tracking disease progression, promoting early interventions.

Clinical Trial Intelligence

Current Clinical Pipeline

It encompasses pipeline by phase, pipeline by company, and pipeline by mechanism.

• Phase I: They evaluate safety, pharmacokinetics, and tolerability.
• Phase II: They help in the assessment of optimal dose, benefits, and efficacy.
• Phase III: They are the large-scale studies evaluating safety and efficacy.
• Approved Products: They encompass products with optimal mechanisms of action, dosing methods, efficacy, and safety.
• Terminated Studies: They refer to the studies terminated due to insufficient efficacy, safety, and clinical benefits.
• Upcoming Regulatory Milestones: They highlight the advancements in next-generation complement pathway inhibitors, gene therapies, and combination therapies.

Regulatory Landscape

Global Regulatory Environment

• FDA: It is a regulatory body that ensures efficacy, safety, and security of human and veterinary drugs to protect human life.
• EMA: A European Union body that evaluates, supervises, and monitors the safety of human and veterinary medicines.
• PMDA: It is Japan’s regulatory agency ensuring the safety, quality, and efficacy of pharmaceuticals and medical devices.
• NMPA: It is China’s regulatory body responsible for ensuring the safety and quality of pharmaceuticals, vaccines, medical devices, and cosmetics.
• MHRA: It ensures the safety, efficacy, and quality of medical devices, medicines, and blood for transfusion across the UK.
• Other Regional Authorities: They encompass CDSCO, SFDA, MOHAP, ANVISA, and MFDS.

Pricing Analysis

Global Therapy Pricing Landscape

It involves comparison of average treatment cost, annual therapy cost, regional pricing comparison, and reimbursement status.

• Complement Inhibitors: Their cost is driven by clinical trial costs, manufacturing complexities, and dosage frequency.
• Nutritional Supplements: The clinical evidence, quality, and consumer demand influence their pricing.
• Cell Therapies: Their pricing factors encompass complex processes, specialized facilities, personalized approach, and efficacy.
• Gene Therapies: Vector development, advanced delivery technologies, efficacy, and reimbursement support are the pricing factors.

Reimbursement Analysis

Healthcare Coverage Across Major Markets

Includes reimbursement support across Medicare, Medicaid, private insurance, along with Japan, China, and European reimbursement policies.

Supply Chain Analysis

Manufacturing and Distribution Network

They encompass operations such as production, manufacturing, sterile packaging, quality control, transportation, and traceability.

• Raw Materials: They involve the use of monoclonal antibodies, viral vectors, stabilizers, and cell culture media.
• Biologic Manufacturing: They include cell line development, fermentation, filtration, quality control, and GMP-compliant facilities.
• Fill-Finish: They focus on aseptic filling, sterile preparation, container closure, and sterility testing.
• Cold Chain: They offer refrigerated storage, temperature-controlled transport, and maintain product integrity.
• Distribution: They encompass major pharmaceutical distributors, retail clinics, and pharmacies.
• Hospital Supply: They include hospital pharmacies, outpatient clinics, and specialty centers.

Investment and Funding Landscape

Capital Flow Across the Industry

They help in accelerating R&D, clinical trials, manufacturing, regulatory approvals, commercialization, and distribution.

• Venture Capital: It supports the development of new products, clinical trials, and R&D activities.
• IPO Activity: They help in late-stage clinical activity, pipeline expansion, and commercialization.
• Strategic Partnerships: They support expansion of R&D activities, access to advanced technologies, and expertise.
• Licensing Deals: They support the development and commercialization of new therapies by leveraging various companies' resources.
• Mergers & Acquisitions: They provide access to new platforms, technologies, and expertise, accelerating product development.
• Government Funding: They support translational research and clinical studies.

Patent Analysis

Intellectual Property Landscape: They cover recent patents, patent expiration, patent trends, innovation hotspots, and technology ownership.

Customer Buying Behavior

Purchasing Decision Analysis

They outline purchasing criteria, brand preference, clinical efficacy, safety, cost-effectiveness, and a decision matrix.

• Physicians: They focus on clinical efficacy, safety profile, administration frequency, and clinical outcomes of the products.
• Hospitals: They include product costs, supply reliability, storage requirements, and reimbursement support.
• Specialty Clinics: They revolve around ease of administration, patient demand, reimbursement support, and product availability.
• Payers: They depend on cost-effectiveness, real-world evidence, budget impact, and reimbursement policies.

Quick Facts Table

Segmental Insights

By Disease Stage Insights

The Intermediate Dry AMD Segment Dominated the Market With 43% in 2025

The intermediate dry AMD segment led the dry age-related macular degeneration market with a 43% share in 2025, driven by growth in monitoring rates and therapeutic interventions, which supported adoption of effective treatment options. Biomarker-based diagnosis improved treatment planning. An aging population increased the prevalence rate and encouraged their use.

The advanced dry AMD (geographic atrophy) segment held the second-largest share of 35% of the market in 2025 and is expected to witness the fastest growth with a CAGR of 11.42% during the forecast period, due to growing approval of complement inhibitors, which expand treatment options. Growing clinical trials improve patient access. As per the survey conducted by Payal Rabde, high unmet medical need also accelerates their innovations.

By Treatment Type Insights

The Complement Inhibitors Segment Dominated the Market With 31% in 2025

The complement inhibitors segment accounted for the highest revenue share of 31% of the dry age-related macular degeneration market in 2025, driven by the commercial launch of targeted therapies, which increased their demand. Expansion of reimbursement policies also improved their accessibility. A strong pipeline also supported their long-term growth.

The cell-based therapies segment held the second-largest share of 9% of the market in 2025 and is expected to show the highest growth during the forecast period, due to stem cell innovations attracting investment. Regenerative medicine advances improve clinical outcomes. Pipeline expansion is also supporting their commercialization.

By Route of Administration Insights

The Intravitreal Injection Segment Dominated the Market With 63% in 2025

The intravitreal injection segment held a major revenue share of 63% of the dry age-related macular degeneration market in 2025, as approved complement inhibitors were primarily used for intravitreal delivery. High clinical efficacy also supported physician preference. Hospital infrastructure also enabled growth in their treatment.

The oral segment held the second-largest share of 16% of the market in 2025 and is expected to expand rapidly with a CAGR of 12.14% during the forecast period, due to oral pipeline therapies, which improve patient convenience. Better compliance also encourages development. Pharmaceutical innovations also expand opportunities.

By End User Insights

The Hospitals Segment Dominated the Market With 42% in 2025

The hospitals segment contributed the biggest revenue share of 42% of the dry age-related macular degeneration market in 2025, as most intravitreal procedures occurred in hospitals. Advanced diagnostic facilities also improved patient management. Strong reimbursement also supported a rise in their treatment volumes.

The ophthalmology clinics segment held the second-largest share of 30% of the market in 2025 and is expected to gain the highest share with a CAGR of 10.34% during the forecast period, due to increasing specialist clinics, which improve accessibility. Dedicated retinal services also attract patients. Outpatient treatment volumes also continue to rise, encouraging their use.

By Distribution Channel Insights

The Hospital Pharmacies Segment Dominated the Market With 46% in 2025

The hospital pharmacies segment held the largest revenue share of 46% of the dry age-related macular degeneration market in 2025, as injectable biologics were mainly dispensed through hospitals. Integrated treatment pathways also improved their efficiency. Based on the analysis of Payal Rabde, institutional procurement also supported a rise in their demand.

The specialty pharmacies segment held the second-largest share of 20% of the market in 2025 and is expected to grow with the fastest CAGR of 11.64% during the forecast period, due to specialty biologics requiring expert handling. Cold-chain infrastructure expands availability. Increasing reimbursement also strengthens their utilization.

Regional Insights

North America Dominated the Market

North America dominated the dry age-related macular degeneration market with 41% in 2025, due to early product approvals and strong reimbursement support, which accelerated adoption rates. High disease prevalence also supported market leadership. Significant R&D investments also sustained innovation. Growth in health awareness and expansion of ophthalmology facilities also increased the adoption of dry age-related macular degeneration treatment options. Their widespread availability also increased their use, which contributed to the market growth.

US Market Trends

U.S. held a 33% share of the market in 2025 and is expected to grow with the highest CAGR of 8.42% during the studied years, driven by a large elderly population, which increased demand for dry age-related macular degeneration treatment options. A robust clinical trial ecosystem also supported innovations, where premium biologic adoption also remained high. According to the information gathered by Payal Rabde, companies like Apellis Pharmaceuticals Inc., with a total revenue for 2025 of 1,003,782, also helped in maintaining its market position.

Mexico Market Trends

Mexico held a 3% share in the dry age-related macular degeneration market in 2025, due to healthcare modernization, which improves ophthalmology access. Urban diagnosis rates continue rising, which increased the demand for dry age-related macular degeneration treatment solutions. Growing private investment also supports their expansion, where a growing geriatric population and health awareness are also increasing their use. A rise in government initiatives is also increasing their use and innovations.

Europe’s Market Gains Momentum

Europe held a 28% share of the dry age-related macular degeneration market and is expected to grow significantly during the forecast period, due to a growing elderly population increasing disease burden. Favorable regulatory pathways improve access to dry age-related macular degeneration treatments. Strong academic research also supports innovations, where well-established healthcare infrastructure also increases their adoption rates. The presence of advanced industries is also driving their innovations, enhancing market growth.

Germany Market Trends

Germany held a 7% share in the dry age-related macular degeneration market in 2025, driven by advanced retinal care infrastructure, which supported treatment. High healthcare spending also improved accessibility to dry age-related macular degeneration treatment options. Clinical research remained strong, where growth in collaborations also accelerated the development of new products. Growth in R&D investments also encouraged their innovations, where high disease awareness improved their adoption rates.

Rest of Europe held a 5% share in the market in 2025 and is expected to witness the fastest growth with a CAGR of 8.91% over the forecast period, due to healthcare modernization expanding treatment availability. Clinical collaborations improve innovation, and aging demographics also sustain demand for dry age-related macular degeneration treatment solutions. Favourable government support also increases their use, and expanding reimbursement policies are also increasing their accessibility.

Asia Pacific Emerges as the Fastest Growing Market

Asia Pacific held a 22% share of the dry age-related macular degeneration market in 2025 and is expected to grow at the fastest CAGR of 10.63% during the forecast period, due to rapid aging population, which increases disease incidence. Healthcare investments also improve access to dry age-related macular degeneration treatments. Expanding clinical research also accelerates their adoption rates. Growing healthcare expenditure and expanding healthcare infrastructure are also promoting market growth.

China Market Trends

China held an 8% share of the dry age-related macular degeneration market in 2025, driven by a large patient population, which enhanced market expansion. Government healthcare reforms also improved access to dry age-related macular degeneration treatment. Domestic innovation also strengthened the pipeline. Growth in health awareness and the presence of advanced imaging technologies also increased their use. Expansion of healthcare expenditures and specialized ophthalmology clinics also increased their use.

India Market Trends

India held a 3% share in the market in 2025 and is expected to expand rapidly with a CAGR of 11.64% in the coming years, due to expanding eye care programs, which improve diagnosis. Healthcare spending continues increasing, which accelerates dry age-related macular degeneration treatment innovations. A large underserved population creates opportunity, where expanding reimbursements support, and R&D activities are also enhancing their advancements. Increasing patient volume is also driving demand.

Expanding Healthcare Boost Latin America’s Market

Latin America held a 5% share in the dry age-related macular degeneration market in 2025 and is expected to show lucrative growth during the forecast period, due to expanding healthcare access and improving diagnosis. Aging demographics increase the prevalence of dry age-related macular degeneration, which drives the demand for their effective treatment options. Public-private investments also support retinal care, encouraging their use. Expanding clinics and hospitals are also propelling market expansion.

Brazil Market Trends

Brazil held a 3% share in the dry age-related macular degeneration market in 2025, driven by the largest regional healthcare market, which increased the demand for dry age-related macular degeneration treatment options. Improved specialist care also supported their adoption. Growth in awareness increased the diagnosis rate, which encouraged adoption. A rise in healthcare expenditures and emerging companies also increased their innovations, while favorable insurance coverage also increased their accessibility.

The rest of Latin America held a 1% share in the market in 2025 and is expected to gain the highest market share with a CAGR of 8.63% during the forecast period, due to improving healthcare infrastructure, which expands access to dry age-related macular degeneration treatments. Government investments also support ophthalmology services, where diagnosis rates continue rising, promoting their use. Increasing awareness and the increasing use of ophthalmologists are also driving up their use to tackle unmet medical needs.

Market Across MEA Driven by Increasing Investments

MEA held a 4% share in the dry age-related macular degeneration market in 2025 and is expected to show notable growth during the forecast period, due to rising healthcare investments which improve specialty eye care. An aging population also supports market expansion, where increasing awareness also drives early diagnosis of dry age-related macular degeneration patients. Expanding healthcare infrastructure and ophthalmology services are also increasing the demand for their treatment options, fueling market growth.

Saudi Arabia Market Trends

Saudi Arabia held a 1.50% share in the dry age-related macular degeneration market in 2025 and is expected to show the fastest growth with a CAGR of 8.72% during the forecast period, driven by high vision care investments, which strengthened treatment capacity. Modern hospitals also improved access to dry age-related macular degeneration treatment options. Government initiatives also supported ophthalmology products adoption, where growth in collaborations also increased their innovations.

UAE Market Trends

United Arab Emirates (UAE) held a 1% share in the market in 2025, due to premium healthcare facilities, which encourage advanced therapies adoption. Expanding medical tourism also supports a rise in the demand for dry age-related macular degeneration treatment options. Specialist services continue expanding, which increases access to these treatment options. Growing dry age-related macular degeneration disease rates and increasing health awareness are also increasing diagnostic rates, which promotes their innovations.

Top Vendors and Their Offerings

Latest Announcement by Industry Leader

In May 2026, after announcing positive results of Phase II clinical trial of QA102 in patients with intermediate dry age-related macular degeneration (AMD), Scott Whitcup, MD, an expert in ophthalmic drug development and Sunil Patel, MD, PhD, a principal investigator of the study, highlighted, "Intermediate AMD represents the most prevalent stage of the disease, yet remains an area of significant unmet medical need with a lack of therapies to slow or prevent progression.". "The phase II data for QA102 are very encouraging for millions of people affected by intermediate or advanced forms of dry age-related macular degeneration."

Recent Developments in the Market

• In July 2026, LYTENAVA (bevacizumab) was announced to have received FDA approval for neovascular age-related macular degeneration (nAMD). IT is the first FDA-approved formulation across the U.S.
• In July 2026, the European commercial launch of PRIMA, which is the first and only treatment restoring functional central vision of patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD), was announced by Science Corporation. Under the European Union Medical Device Regulation from DEKRA, the product also received a CE (Conformité Européenne) mark.

Competitive Landscape

Market Competition Overview

• It highlights the degree of competition, market concentration, innovation intensity, pricing dynamics, and strategic positioning of leading companies.
• Competitive Positioning Matrix: It depends on Product portfolio, Geographic reach, Innovation capability, Pipeline strength, and Commercial presence.
• Market Share Analysis: It covers product portfolio, geographical presence, regulatory compliance, and manufacturing capabilities.
• Strategic Developments: It outlines Product launches, Regulatory approvals, Collaborations, Partnerships, Acquisitions, Licensing agreements, and Manufacturing expansions.
• Porter’s Five Forces Analysis: It encompasses Supplier power, Buyer power, Threat of substitutes, Threat of new entrants, and Competitive rivalry.

Market Companies

Alcon Inc.

Mighty Therapeutics

Ocugen, Inc.

Strategic Benchmarking

Company Comparison Dashboard: It compares companies' revenues, R&D expenditure, pipeline, geographic reach, approved products, clinical trials, partnerships, manufacturing capabilities, and benchmarking matrix.

Market Opportunity Assessment

High-Growth Investment Areas: They encompass growing incidence of geographic atrophy, rising development of complement inhibitors, oral therapies, gene therapy, stem cell therapy, AI diagnostics, long-acting delivery platforms, and emerging markets.

Future Market Outlook (2026–2035)

Market Evolution Over the Next Decade

It evaluates how scientific advances, regulatory developments, demographic shifts, healthcare investments, reimbursement improvements, and commercialization strategies are expected to reshape the market.

• Revenue Outlook: It will be driven by growing GA diagnosis, approval of new therapies, and expansion of reimbursement policies.
• Innovation Outlook: They focus on advancements in complement pathway inhibitors, gene therapies, companion diagnostics, and AI-powered platforms.
• Competitive Outlook: It is expected to rise due to expansion of manufacturing capabilities, partnerships, and acquisitions.
• Regional Outlook: It depends on diagnostic rates, reimbursement support, healthcare investments, and the geriatric population.
• Investment Outlook: They are driven by strong innovations, investment in regenerative medicines, expanding manufacturing capabilities, and new acquisitions.
• Technology Outlook: They are involved in advancements in AI imaging solutions, OCT imaging technologies, gene editing platforms, remote patient monitoring solutions, and drug delivery systems.

Strategic Recommendations

Actionable Business Recommendations

It focuses on product development priorities, partnership strategies, market entry approaches, manufacturing expansion, reimbursement planning, commercialization, portfolio diversification, and long-term competitive positioning.

• Pharmaceutical Companies: They should focus on GA therapies, next-generation complement inhibitors, and strategic collaborations.
• Biotechnology Companies: They are expected to accelerate clinical development of new therapies, adopt new platform technologies, and collaborate with pharma companies.
• Investors: They should focus on gene therapies, AI diagnostics, and regenerative medicines.
• Healthcare Providers: They should improve early diagnosis, adoption of advanced imaging technologies, treatment adherence, and advanced monitoring solutions.
• CDMOs: They should focus on sterile fill-finished procedures, quality control, and advanced manufacturing technologies.
• Distributors: They should improve logistics networks, enhance uninterrupted supply, and improve product monitoring.
• Policymakers: They should support innovative therapies, enhance reimbursement support, and promote awareness initiatives.
• New Market Entrants: They should develop affordable therapies, sustained drug delivery solutions, and AI-based diagnostics.

Analyst Opinion

Based on Payal Rabde's analysis, the dry age-related macular degeneration market is expected to show significant growth during the forecast period due to a wide range of factors. The growth in geriatric populations, advanced therapies, retinal clinics, complementary therapy, and cell and gene therapies are increasing the demand for dry age-related macular degeneration diagnostic and treatment options. Advancements in biomarker-based monitoring, AI imaging, remote monitoring, stem cell platforms, and sustained drug delivery systems are also driving their expansion. Additionally, segments such as advanced dry AMD (geographic atrophy), cell-based therapies, oral, ophthalmology clinics, and specialty pharmacies are expanding to show considerable growth, driving new investment opportunities. Similarly, companies like Apellis Pharmaceuticals, Astellas Pharma Inc., Alcon, Inc., Alkeus Pharmaceuticals, Mighty Therapeutics, Annexon Biosciences, and Ocugen, Inc. are anticipated to expand notably, which will attract new investments and funding.

Segments Covered in the Report

By Disease Stage

• Early Dry AMD
• Intermediate Dry AMD
• Advanced Dry AMD (Geographic Atrophy)
  • Foveal Geographic Atrophy
  • Non-Foveal Geographic Atrophy

By Treatment Type

• Complement Inhibitors
  • C3 Inhibitors
  • C5 Inhibitors
• Neuroprotective Therapies
• Cell-Based Therapies
  • Stem Cell Therapy
  • Retinal Pigment Epithelium (RPE) Cell Therapy
• Gene Therapy
• Nutritional Supplements
  • AREDS2 Formulations
  • Antioxidant Vitamins
  • Zinc-Based Supplements
• Low Vision Rehabilitation Devices
• Supportive Care

By Route of Administration

• Intravitreal Injection
• Oral
• Topical
• Implantable Delivery Systems

By End User

• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers
• Specialty Eye Care Centers
• Home Care Settings

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada 
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina 
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany
    • Italy 
    • France 
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland 
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan 
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries 
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait 
    • Oman 
    • Bahrain
  • South Africa 
  • Egypt 
  • Rest of MEA